- MK-8617
-
- $40.00
-
2026-07-14
- CAS:1187990-87-9
- Purity: 99.63%
- Supply Ability: 10g
- MK-8617
-
- $2.00
-
2020-01-09
- CAS:1187990-87-9
- Min. Order: 1g
- Purity: 98%min
|
| | MK-8617 Basic information |
| Product Name: | MK-8617 | | Synonyms: | N-(bis(4-methoxyphenyl)methyl)-6-oxo-2-(pyridazin-3-yl)-1,6-dihydropyrimidine-5-carboxamide;5-Pyrimidinecarboxamide,N-[bis(4-methoxyphenyl)methyl]-1,6-dihydro-6-oxo-2-(3-pyridazinyl)-;MK-8617;N-(bis(4-Methoxyphenyl)Methyl)-4-hydroxy-2-(pyridazin-3-yl)pyriMidine-5-carboxaMide;CS-2700;MK 8617;MK8617;N-[BIS(4-METHOXYPHENYL)METHYL]-6-OXO-2-PYRIDAZIN-3-YL-1H-PYRIMIDINE-5-CARBOXAMIDE;MK-8617,MK 8617,HIF-PH,inhibit,Hypoxia-inducible factors,HIFs,Inhibitor,HIF/HIF Prolyl-Hydroxylase | | CAS: | 1187990-87-9 | | MF: | C24H21N5O4 | | MW: | 443.45 | | EINECS: | | | Product Categories: | | | Mol File: | 1187990-87-9.mol |  |
| | MK-8617 Chemical Properties |
| density | 1.32±0.1 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | DMSO:5.67(Max Conc. mg/mL);12.79(Max Conc. mM)
DMSO:PBS (pH 7.2) (1:3):0.25(Max Conc. mg/mL);0.56(Max Conc. mM)
DMF:1.0(Max Conc. mg/mL);2.25(Max Conc. mM) | | form | A solid | | pka | 5.54±0.50(Predicted) | | color | White to off-white |
| | MK-8617 Usage And Synthesis |
| Uses | MK-8617 is a potent, selective and bioavailable hypoxia-inducible factor prolyl hydroxylase 1-3 (HIF PHD1-3) inhibitor used in the treatment of anemia. | | in vivo | Tritiated MK-8617 exhibits minimal metabolic turnover in liver microsomes from rat, dog, and monkey (<10% turover) but significant turnover in human liver microsomes (34% turnover) after 60 min (10 μM MK-8617, 1 mg/mL microsomal protein). In terms of its pharmacokinetic profile, MK-8617 shows good oral bioavailability across species (36 to 71%), with low clearance and volume of distribution. After 48 h treatment of MK-8617, postdose recovery of the radioactivity is about 26% bile, 12% urine, and 38% in feces, indicating that ~38% of the MK-8617 is absorbed and eliminated into bile and urine which is consistent with the oral bioavailability (~36%) observed in the rat study. MK-8617 also elicits an increase in erythropoietin (EPO) levels with a mouse MED of 1.5 mpk when dosed iv[1]. |
| | MK-8617 Preparation Products And Raw materials |
|